These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
159 related articles for article (PubMed ID: 16697107)
41. A gene expression profile of tumor suppressor genes commonly methylated in bladder cancer. Christoph F; Hinz S; Kempkensteffen C; Weikert S; Krause H; Schostak M; Schrader M; Miller K J Cancer Res Clin Oncol; 2007 Jun; 133(6):343-9. PubMed ID: 17160380 [TBL] [Abstract][Full Text] [Related]
42. Correlation between promoter hypermethylation of GSTP1 and response to chemotherapy in diffuse large B cell lymphoma. Nakamichi I; Tomita Y; Zhang B; Sugiyama H; Kanakura Y; Fukuhara S; Hino M; Kanamaru A; Ogawa H; Aozasa K Ann Hematol; 2007 Aug; 86(8):557-64. PubMed ID: 17508213 [TBL] [Abstract][Full Text] [Related]
43. Methylation patterns of Rb1 and Casp-8 promoters and their impact on their expression in bladder cancer. Malekzadeh K; Sobti RC; Nikbakht M; Shekari M; Hosseini SA; Tamandani DK; Singh SK Cancer Invest; 2009 Jan; 27(1):70-80. PubMed ID: 19160091 [TBL] [Abstract][Full Text] [Related]
44. Methylation of tumour suppressor genes APAF-1 and DAPK-1 and in vitro effects of demethylating agents in bladder and kidney cancer. Christoph F; Kempkensteffen C; Weikert S; Köllermann J; Krause H; Miller K; Schostak M; Schrader M Br J Cancer; 2006 Dec; 95(12):1701-7. PubMed ID: 17133271 [TBL] [Abstract][Full Text] [Related]
45. Mapping geographic zones of cancer risk with epigenetic biomarkers in normal breast tissue. Yan PS; Venkataramu C; Ibrahim A; Liu JC; Shen RZ; Diaz NM; Centeno B; Weber F; Leu YW; Shapiro CL; Eng C; Yeatman TJ; Huang TH Clin Cancer Res; 2006 Nov; 12(22):6626-36. PubMed ID: 17121881 [TBL] [Abstract][Full Text] [Related]
46. Evaluation of DAPK gene methylation and HPV and EBV infection in cervical cells from patients with normal cytology and colposcopy. Lattario F; Furtado YL; Silveira FA; do Val IC; Almeida G; da Costa Carvalho Mda G Arch Gynecol Obstet; 2008 Jun; 277(6):505-9. PubMed ID: 18026971 [TBL] [Abstract][Full Text] [Related]
47. Aberrant methylation of E-cadherin and H-cadherin genes in nonsmall cell lung cancer and its relation to clinicopathologic features. Kim DS; Kim MJ; Lee JY; Kim YZ; Kim EJ; Park JY Cancer; 2007 Dec; 110(12):2785-92. PubMed ID: 17960794 [TBL] [Abstract][Full Text] [Related]
49. Differentiation of seminomatous from nonseminomatous testicular tumors with MR imaging. Johnson JO; Mattrey RF; Phillipson J AJR Am J Roentgenol; 1990 Mar; 154(3):539-43. PubMed ID: 2106218 [TBL] [Abstract][Full Text] [Related]
50. Expression of mammalian paralogues of HRAD9 and Mrad9 checkpoint control genes in normal and cancerous testicular tissue. Hopkins KM; Wang X; Berlin A; Hang H; Thaker HM; Lieberman HB Cancer Res; 2003 Sep; 63(17):5291-8. PubMed ID: 14500360 [TBL] [Abstract][Full Text] [Related]
51. Distinguishing epigenetic features of preneoplastic testis tissues adjacent to seminomas and nonseminomas. Gainetdinov IV; Kondratieva SA; Skvortsova YV; Zinovyeva MV; Stukacheva EA; Klimov A; Tryakin AA; Azhikina TL Oncotarget; 2016 Apr; 7(16):22439-47. PubMed ID: 26843623 [TBL] [Abstract][Full Text] [Related]
52. Involvement of adenomatous polyposis coli (APC) gene in testicular yolk sac tumor of infants. Kato N; Shibuya H; Fukase M; Tamura G; Motoyama T Hum Pathol; 2006 Jan; 37(1):48-53. PubMed ID: 16360415 [TBL] [Abstract][Full Text] [Related]
53. Methylation profiles in breast cancer. Buyru N; Altinisik J; Ozdemir F; Demokan S; Dalay N Cancer Invest; 2009 Mar; 27(3):307-12. PubMed ID: 19194828 [TBL] [Abstract][Full Text] [Related]
54. Urothelial carcinomas arising in arsenic-contaminated areas are associated with hypermethylation of the gene promoter of the death-associated protein kinase. Chen WT; Hung WC; Kang WY; Huang YC; Chai CY Histopathology; 2007 Dec; 51(6):785-92. PubMed ID: 17953697 [TBL] [Abstract][Full Text] [Related]
56. Expression of EBV latent antigens, mammalian target of rapamycin, and tumor suppression genes in EBV-positive smooth muscle tumors: clinical and therapeutic implications. Ong KW; Teo M; Lee V; Ong D; Lee A; Tan CS; Vathsala A; Toh HC Clin Cancer Res; 2009 Sep; 15(17):5350-8. PubMed ID: 19706821 [TBL] [Abstract][Full Text] [Related]
57. p53 expression and tumor proliferative activity in testicular germ-cell tumors. Ehteshami M; Ro J; Shin H; Lee J; Ordonez N; Ayala A Int J Oncol; 1996 Oct; 9(4):787-93. PubMed ID: 21541584 [TBL] [Abstract][Full Text] [Related]
58. Aberrant expression and distribution of the OCT-4 transcription factor in seminomas. Cheng CJ; Wu YC; Shu JA; Ling TY; Kuo HC; Wu JY; Chang EE; Chang SC; Huang YH J Biomed Sci; 2007 Nov; 14(6):797-807. PubMed ID: 17682839 [TBL] [Abstract][Full Text] [Related]
59. Epigenetic abnormalities in cutaneous squamous cell carcinomas: frequent inactivation of the RB1/p16 and p53 pathways. Murao K; Kubo Y; Ohtani N; Hara E; Arase S Br J Dermatol; 2006 Nov; 155(5):999-1005. PubMed ID: 17034532 [TBL] [Abstract][Full Text] [Related]
60. Alterations of the p53 tumor suppressor gene in carcinoma in situ of the testis. Kuczyk MA; Serth J; Bokemeyer C; Jonassen J; Machtens S; Werner M; Jonas U Cancer; 1996 Nov; 78(9):1958-66. PubMed ID: 8909317 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]